glp 1 gen 5 GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome or efficacy. The science around GLP-1 drugs

NPR Shots

(2013) 8:e63197

This analysis describes cost and utilization of GLP-1 medications in Utah using data from the Utah All-Payer Claims Database for commercial (20192023) and Medicaid markets (2019-2022) and CMS 100% Medicare files (20212022), segmented by market and year

Tirzepatide for managing overweight and obesity (TA1026): nice.org.uk/guidance/ta1026 NICE

Indeed, there are multiple primary or secondary bile acid chemosensors in the liver (348, 354) or scattered along the gastrointestinal tract (355), where they ensure a direct negative feedback aiding detoxification (356) and protecting from hepatotoxicity and carcinogenicity displayed by some secondary bile salt such as lithocholic acid

To successfully employ an all-comers strategy moving forward, manufacturers need to ensure products have strong clinical and/or non-clinical differentiation, a robust data package that addresses a range of patient types and comorbidities, and well-funded physician and patient facing marketing campaigns